
Whitehawk Therapeutics rose 45.3% from $2.12 to $3.08, ahead of the S&P 500's +10.0%. Its worst day was Mar 27 (−11.5%), and its low came Nov 20 at $1.99.
Nov 17, 2025 – Nov 17, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Whitehawk Therapeutics closed at its lowest level of the year, 6.1% below where the year started.
−4.8% · S&P 500 −1.5%
Whitehawk Therapeutics shares rose 14.3%, while the S&P 500 rose 0.1%.
+14.3% · S&P 500 +0.1%
Story events cover the past 12 months · Times ET
EPS of $-0.34 beat the $-0.38 estimate on $0.00 revenue (est. $20.0M).
−2.7% · S&P 500 −1.5%
Whitehawk Therapeutics shares fell 11.5%, while the S&P 500 fell 1.7%.
−11.5%, the year's worst day · S&P 500 −1.7%
Whitehawk Therapeutics shares rose 15.3%, while the S&P 500 rose 1.2%.
+15.3% · S&P 500 +1.2%
EPS of $-0.32 beat the $-0.33 estimate on $0.00 revenue.
−5.1% · S&P 500 −0.3%
EPS of $-0.20 beat the $-0.28 estimate on $0.00 revenue.
+15.5% · S&P 500 −0.2%
EPS of $-0.23 beat the $-0.24 estimate on $0.00 revenue (est. $-383,330.00).
+2.9% · S&P 500 +2.4%
Where it ended: a close of $3.08 on Nov 17, 2026. Up next: Q4 2026 earnings on Mar 11, 2027 (EPS est. $-0.23, revenue est. $-766,670.00).
Nothing in the past 12 months.
All WHWK dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for WHWK and SPY from Benzinga historical bars. Not investment advice.